GB Sciences, Inc. (GBLX) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
GB Sciences, Inc. (GBLX) trades at $0.0003 with AI Score 49/100 (Grade C). GB Sciences, Inc. is a biotechnology company focused on the research and development of plant-based medicines. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for GBLX: GBLX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates GBLX against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
GBLX: 1/3 scored disciplines lean bearish. Dominant signal: Izzy Englander bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
GB Sciences, Inc. (GBLX) Healthcare & Pipeline Overview
GB Sciences, Inc., operating in the biotechnology sector, researches and develops plant-based medicines, including cannabinoid-inspired therapies, targeting conditions like Parkinson's disease and neuropathic pain. With pre-clinical programs and a focus on complex therapeutic mixtures, the company aims to serve the prescription drug market in North America and Europe.
What Is the Investment Thesis for GBLX?
GB Sciences, Inc. presents a high-risk, high-reward investment profile characteristic of early-stage biotechnology firms. The company's focus on plant-based medicines, particularly cannabinoid-inspired therapies, aligns with growing market interest in alternative treatments. However, with a market capitalization of $0.00B and negative profitability (P/E of -0.28 and a profit margin of -299.6%), the company's financial stability is a significant concern. The company's gross margin is 100.0%. The success of GB Sciences hinges on advancing its pre-clinical programs to clinical trials and ultimately securing regulatory approvals. The high beta of 9.86 indicates extreme volatility. Investors should carefully consider the risks associated with OTC-traded companies and the uncertainty inherent in pharmaceutical development.
Based on FMP financials and quantitative analysis
GBLX Key Highlights
Market Cap of $0.00B reflects the company's small size and early stage of development.
- P/E Ratio of -0.28 indicates the company is not currently profitable.
- Profit Margin of -299.6% demonstrates significant losses relative to revenue.
- Gross Margin of 100.0% suggests high potential profitability if research and development costs can be managed effectively.
- Beta of 9.86 indicates the stock is significantly more volatile than the market average.
Who Are GBLX's Competitors?
GBLX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are GBLX's Key Strengths?
Focus on plant-based medicines.
- Intellectual property portfolio.
- Pre-clinical programs targeting unmet medical needs.
- Expertise in cannabinoid-inspired therapies.
What Are GBLX's Weaknesses?
Limited financial resources.
- Small team size.
- Early stage of development.
- Dependence on external funding and partnerships.
What Could Drive GBLX Stock Higher?
Announcement of results from pre-clinical studies for Parkinson's disease program (timeline: next 6-12 months).
- Initiation of clinical trials for neuropathic pain therapy (timeline: next 12-18 months, contingent on funding).
- Pursuit of strategic partnerships with larger pharmaceutical companies.
- Expansion of intellectual property portfolio through new patent filings.
- Research and development efforts to advance drug candidates through the pipeline.
What Are the Key Risks for GBLX?
Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Failure to secure funding for clinical trials.
- Negative results from clinical trials.
- Regulatory delays or rejection of drug candidates.
- Competition from larger biotechnology companies with greater resources.
- Limited financial resources and dependence on external funding.
What Are the Growth Opportunities for GBLX?
- Advancement of Parkinson's Disease Program: GB Sciences has a pre-clinical program targeting Parkinson's disease. The Parkinson's disease treatment market is projected to reach $5.6 billion by 2027. Successfully transitioning this program to clinical trials and demonstrating efficacy could unlock significant value for the company. The timeline for this catalyst depends on securing funding and completing pre-clinical studies, potentially leading to clinical trials within the next 2-3 years.
- Development of Neuropathic Pain Therapies: The company is developing plant-based medicines for neuropathic pain, a market estimated at $8.3 billion globally. Achieving positive results in pre-clinical studies and advancing to clinical trials could position GB Sciences as a player in this large and growing market. This growth opportunity is contingent on successful pre-clinical data, which could lead to clinical trial initiation within 2-3 years.
- Expansion into Cardiovascular Therapeutics: GB Sciences has a cardiovascular therapeutic program in the pre-clinical stage. The global cardiovascular disease market is substantial, offering significant potential for new therapies. Progressing this program through pre-clinical and clinical stages could diversify the company's pipeline and create new revenue streams. This is a longer-term opportunity, with potential clinical trials 3-5 years out.
- Commercialization of COVID-Related Cytokine Release Syndrome Treatment: GB Sciences is researching treatments for COVID-related cytokine release syndrome. While the urgency of the COVID-19 pandemic has decreased, there remains a need for effective treatments for complications arising from the virus. Successful development and commercialization of such a treatment could provide a near-term revenue opportunity. This opportunity depends on ongoing research and potential regulatory pathways, possibly yielding results within the next 1-2 years.
- Strategic Partnerships and Licensing Agreements: GB Sciences can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its drug candidates. Licensing agreements can provide upfront payments, milestone payments, and royalties, generating revenue and validating the company's technology. The timing and success of such partnerships are uncertain but represent a potential growth driver in the near to medium term.
What Threats Does GBLX Face?
- Regulatory hurdles and approval processes.
- Competition from larger biotechnology companies.
- Uncertainty in clinical trial outcomes.
- Fluctuations in market demand for plant-based therapies.
What Are GBLX's Competitive Advantages?
- Intellectual property portfolio covering various therapeutic areas.
- Expertise in developing cannabinoid-inspired medicines.
- Focus on plant-based therapies, aligning with growing market trends.
- Proprietary formulations and drug delivery systems.
What Does GBLX Do?
GB Sciences, Inc., founded in 2001 and based in Las Vegas, Nevada, is a biotechnology company dedicated to the research and development of plant-based medicines. Originally incorporated as Growblox Sciences, Inc., the company rebranded in October 2016 to reflect its evolving focus. GB Sciences develops cannabinoid-inspired medicines and complex therapeutic mixtures intended for the prescription drug market. Their research spans a range of conditions, including Parkinson's disease, neuropathic pain, chronic pain, COVID-related cytokine release syndrome, depression/anxiety, and cardiovascular ailments. The company's intellectual property portfolio covers these therapeutic areas, with programs currently in the pre-clinical animal stage. GB Sciences operates in both North America and Europe, seeking to bring innovative, plant-based solutions to address unmet medical needs. Their strategy involves rigorous scientific investigation and the development of proprietary formulations to create effective and safe therapies. With a small team of 2 employees, the company outsources many functions. GB Sciences is positioned to capitalize on the growing acceptance of plant-based medicines and the increasing demand for novel therapeutic options.
What Products and Services Does GBLX Offer?
- Researches and develops plant-based medicines.
- Focuses on cannabinoid-inspired therapies.
- Targets conditions like Parkinson's disease, neuropathic pain, and chronic pain.
- Develops complex therapeutic mixtures for the prescription drug market.
- Conducts pre-clinical animal studies to evaluate drug candidates.
- Seeks to create innovative and effective treatments for unmet medical needs.
- Operates in North America and Europe.
How Does GBLX Make Money?
- Develops proprietary plant-based medicine formulations.
- Out-licenses or partners with larger pharmaceutical companies for clinical trials and commercialization.
- Generates revenue through licensing fees, milestone payments, and royalties.
What Industry Does GBLX Operate In?
GB Sciences operates within the biotechnology industry, a sector characterized by high innovation, intense competition, and significant regulatory hurdles. The market for plant-based medicines is expanding, driven by increasing consumer interest in natural and alternative therapies. However, the industry is also subject to stringent regulations and lengthy approval processes. GB Sciences competes with other biotechnology companies, including ACUS, BIOAF, EHOS, GSTC and HTDS, some of which have greater resources and more advanced clinical programs. Success in this industry requires strong scientific expertise, effective regulatory strategies, and substantial capital investment.
Who Are GBLX's Key Customers?
- Pharmaceutical companies seeking novel drug candidates.
- Patients with conditions like Parkinson's disease, neuropathic pain, and chronic pain.
- Healthcare providers prescribing plant-based medicines.
Key Financial Metrics
Return on equity for GB Sciences, Inc. stands at 28.0%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.02 means current liabilities exceed short-term assets, a liquidity point worth watching.
GB Sciences, Inc. (GBLX) Valuation Context
Relative to its peer group, GBLX's quantitative score of 49/100 is below the peer average of 76/100.
Company Profile
GB Sciences, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Las Vegas, US. The company is led by CEO Andrea Small-Howard. GBLX has traded publicly since 2008.
Financial Health
GB Sciences, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
GBLX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Focus on plant-based medicines.
- Intellectual property portfolio.
- Pre-clinical programs targeting unmet medical needs.
- Expertise in cannabinoid-inspired therapies.
Bear Case
- Limited financial resources.
- Small team size.
- Early stage of development.
- Dependence on external funding and partnerships.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2024 | $97,235 | -$100,355 | -$0.0002 |
Based on FMP financials and quantitative analysis
GBLX Latest News
No recent news available for GBLX.
GBLX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GBLX.
Price Targets
Wall Street price target analysis for GBLX.
GBLX MoonshotScore
What does this score mean?
The MoonshotScore rates GBLX 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Andrea Small-Howard
Chief Executive Officer
Andrea Small-Howard serves as the Chief Executive Officer of GB Sciences, Inc. Her background includes experience in the pharmaceutical and biotechnology industries. She has a strong understanding of drug development, regulatory affairs, and commercialization strategies. Her expertise is crucial for guiding GB Sciences through its pre-clinical and clinical development programs. She is responsible for overseeing the company's overall strategy and operations, including research and development, business development, and investor relations.
Track Record: Under Andrea Small-Howard's leadership, GB Sciences has focused on advancing its pre-clinical programs and expanding its intellectual property portfolio. She has been instrumental in securing funding and establishing strategic partnerships to support the company's growth. Her leadership is focused on driving innovation and creating value for shareholders through the development of novel plant-based medicines. She is managing 2 employees.
GBLX OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that GB Sciences may not meet the minimum financial or disclosure requirements of the higher tiers (OTCQX and OTCQB). Companies on this tier may have limited financial reporting, making it more difficult for investors to assess their financial health and performance compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries a higher degree of risk due to the lack of regulatory oversight and transparency.
- OTC Tier: OTC Other
- Limited financial disclosure increases information asymmetry.
- Low trading volume and liquidity can lead to price volatility.
- Higher potential for fraud and manipulation compared to listed exchanges.
- OTC Other tier status indicates potential financial or operational challenges.
- Dependence on external funding and partnerships.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's intellectual property portfolio and competitive landscape.
- Evaluate the company's funding sources and cash runway.
- Understand the risks associated with investing in OTC-traded companies.
- Consult with a financial advisor before making any investment decisions.
- Confirm the company's good standing with the state of incorporation.
- Focus on research and development of plant-based medicines.
- Intellectual property portfolio covering various therapeutic areas.
- CEO with experience in the pharmaceutical and biotechnology industries.
- Company incorporated in 2001.
GB Sciences, Inc. Healthcare Stock: Key Questions Answered
What does the AI Score mean for GBLX?
GBLX holds an AI Score of 49/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. GB Sciences, Inc. is a biotechnology company focused on the research and development of plant-based medicines. They target conditions like Parkinson's disease and chronic pain …
What does GB Sciences, Inc. do?
GB Sciences, Inc. is a biotechnology company focused on the research and development of plant-based medicines, particularly cannabinoid-inspired therapies. The company aims to create complex therapeutic mixtures for the prescription drug market, targeting conditions such as Parkinson's disease, neuropathic pain, chronic pain, and COVID-related cytokine release syndrome.
What do analysts say about GBLX stock?
As of March 17, 2026, there is no readily available analyst coverage or consensus on GB Sciences, Inc. (GBLX) due to its OTC listing and small market capitalization. Investors should conduct their own thorough due diligence and consider the risks associated with investing in OTC-traded companies.
What are the main risks for GBLX?
The main risks for GB Sciences, Inc. include its limited financial resources, dependence on external funding, and the inherent uncertainties of drug development. The company's pre-clinical programs face the risk of failure in clinical trials or regulatory rejection. Competition from larger biotechnology companies with greater resources poses a significant challenge.
What are the key factors to evaluate for GBLX?
GB Sciences, Inc. (GBLX) holds an AI score of 49/100 (low). presents a high-risk, high-reward investment profile characteristic of early-stage biotechnology firms. Not financial advice.
How frequently does GBLX data refresh on this page?
GBLX's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven GBLX's recent stock price performance?
GB Sciences, Inc. (GBLX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on plant-based medicines. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider GBLX overvalued or undervalued right now?
GB Sciences, Inc. (GBLX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research GBLX before investing?
Before investing in GB Sciences, Inc. (GBLX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available company information and may be limited due to the company's OTC listing.
- AI analysis pending for GBLX.